Enfusion (NYSE:ENFN) Hits New 1-Year High After Analyst Upgrade

Enfusion, Inc. (NYSE:ENFN) shares reached a new 52-week high on Monday after Piper Sandler raised their price target on the stock from $10.00 to $11.50. Piper Sandler currently has a neutral rating on the stock. Enfusion traded as high as $11.50 and last traded at $11.50, with a volume of 224 shares traded. The stock had previously closed at $10.63.

Separately, Stifel Nicolaus boosted their price objective on Enfusion from $11.00 to $13.00 and gave the company a “buy” rating in a report on Wednesday, December 18th. Three investment analysts have rated the stock with a sell rating, one has given a hold rating and two have given a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $10.25.

Insider Buying and Selling at Enfusion

In related news, COO Neal Pawar sold 21,801 shares of the company’s stock in a transaction that occurred on Monday, December 2nd. The stock was sold at an average price of $10.03, for a total value of $218,664.03. Following the sale, the chief operating officer now owns 1,143,544 shares of the company’s stock, valued at approximately $11,469,746.32. This represents a 1.87 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 36.44% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the business. Scalar Gauge Management LLC raised its stake in Enfusion by 21.8% during the second quarter. Scalar Gauge Management LLC now owns 613,513 shares of the company’s stock worth $5,227,000 after purchasing an additional 110,000 shares during the period. Wellington Management Group LLP raised its position in shares of Enfusion by 6.7% in the 3rd quarter. Wellington Management Group LLP now owns 976,296 shares of the company’s stock worth $9,265,000 after buying an additional 61,032 shares during the period. Renaissance Technologies LLC boosted its holdings in Enfusion by 167.6% in the second quarter. Renaissance Technologies LLC now owns 97,100 shares of the company’s stock valued at $827,000 after acquiring an additional 60,811 shares during the last quarter. PDT Partners LLC purchased a new stake in Enfusion during the third quarter valued at about $867,000. Finally, Squarepoint Ops LLC acquired a new stake in Enfusion during the second quarter worth about $683,000. 81.05% of the stock is currently owned by institutional investors and hedge funds.

Enfusion Stock Performance

The company has a market capitalization of $1.36 billion, a PE ratio of 264.57, a P/E/G ratio of 3.98 and a beta of 0.97. The business has a fifty day moving average price of $9.74 and a 200 day moving average price of $9.02.

Enfusion Company Profile

Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.